# US 8,785,602 B2 · EMP2 antibodies and methods of use thereof for causing regression of a solid tumor or symptoms thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,785,602 B2 - Document ID: US8785602B2 - Status: Granted - Kind: B2 - Application number: 14/064,956 - Filed: 2013-10-28 - Published: 2014-03-13 - Granted: 2014-07-22 - Earliest claimed: 2005-04-15 - Assignees: The Regents of the University of California - Applicants: The Regents of the University of California - Inventors: Jonathan Braun; Lynn K. Gordon; Kaori Shimazaki Dadgostar; Madhuri Wadehra; Kathleen A. Kelly; Anna M. Wu - Web page: https://patentgrep.com/patent/US8785602B2 ## CPC - C07K 16/30: from tumour cells - C07K 16/125: {from Chlamydiales (O)} - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/622: Single chain antibody (scFv) - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2. ## Claims ### Claim 1 An isolated antibody that competes for binding to the extracellular loop of a human Epithelial Membrane Protein2 (EMP2) (SEQ ID NO:42) with an EMP2 inhibitor, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three heavy chain complementary determining regions (HCDRs) and wherein the light chain variable region comprises three light chain variable regions (LCDRs), wherein: the sequence of HCDR1 is SEQ ID NO:14, the sequence of HCDR2 is SEQ ID NO:16, the sequence of HCDR3 is SEQ ID NO:37, the sequence of LCDR1 is SEQ ID NO:19, the sequence of LCDR2 is SEQ ID NO:22, and the sequence of LCDR3 is SEQ ID NO:38. ### Claim 2 (depends on 1) The antibody of claim 1, wherein the antibody is a monoclonal antibody, a humanized monoclonal antibody, a human antibody, a diabody, minibody, or triabody, a chimeric antibody, or a recombinant antibody. ### Claim 3 (depends on 1) The antibody of claim 1, wherein the antibody is in scFv, minibody, diabody, or triabody format. ### Claim 4 (depends on 1) The antibody of claim 1, wherein the antibody is conjugated to a cytotoxic agent or a label. ### Claim 5 (depends on 1) A pharmaceutical composition comprising the antibody of claim 1 and a physiologically acceptable carrier. ### Claim 6 (depends on 1) A method for causing regression of a solid tumor or symptoms thereof in a subject the method comprising the administration of an effective amount of an antibody that binds to Epithelial Membrane Protein2 (EMP2) wherein the antibody comprises the three HCDRs and the three LCDRs of the antibody of claim 1. ### Claim 7 (depends on 6) The method of claim 6, wherein the cancer is selected from the group consisting of ovarian cancer, glioblastoma, breast cancer, prostate cancer, testicular cancer and myeloma. ### Claim 8 (depends on 6) The method of claim 6, wherein the cancer is endometrial cancer. ### Claim 9 An isolated antibody which binds to Epithelial Membrane Protein 2 (EMP2), wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three heavy chain complementary determining regions (HCDRs) and wherein the light chain variable region comprises three light chain variable regions (LCDRs), wherein: the sequence of HCDR1 is SEQ ID NO:14, the sequence of HCDR2 is SEQ ID NO:16, the sequence of HCDR3 is SEQ ID NO:37, the sequence of LCDR1 is SEQ ID NO:19, the sequence of LCDR2 is SEQ ID NO:22, and the sequence of LCDR3 is SEQ ID NO:38. ### Claim 10 (depends on 9) The antibody of claim 9, wherein the antibody is a monoclonal antibody, a humanized monoclonal antibody, a human antibody, a diabody, minibody, or triabody, a chimeric antibody, or a recombinant antibody. ### Claim 11 (depends on 9) The antibody of claim 9, wherein the antibody is in scFv, minibody, diabody, or triabody format. ### Claim 12 (depends on 9) The antibody of claim 9, wherein the antibody is conjugated to a cytotoxic agent or a label. ### Claim 13 (depends on 9) A pharmaceutical composition comprising the antibody of claim 9 and a physiologically acceptable carrier. ### Claim 14 (depends on 9) A method for causing regression of a solid tumor or symptoms thereof in a subject the method comprising the administration of an effective amount of an antibody that binds to Epithelial Membrane Protein 2 (EMP2) wherein the antibody comprises the three HCDRs and the three LCDRs of the antibody of claim 9. ### Claim 15 (depends on 14) The method of claim 14, wherein the cancer is selected from the group consisting of ovarian cancer, glioblastoma, breast cancer, prostate cancer, testicular cancer and myeloma. ### Claim 16 (depends on 1) The method of claim 1, wherein the cancer is endometrial cancer.